Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study

María Inmaculada Domínguez-Mozo¹, Lorena López-Lozano², Silvia Pérez-Pérez³, Ángel García-Martínez¹, María José Torrejón², Rafael Arroyo³ and Roberto Álvarez-Lafuente*¹

¹Grupo Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. ²Servicio de Análisis Clínicos, Instituto de Medicina del Laboratorio, Hospital Clínico San Carlos, Madrid, Spain. ³Servicio Neurología, Hospital Universitario Quirónsalud Madrid, Madrid, Spain

Objectives: 1. To analyze the prevalence and levels of anti-EBNA-1 and anti-VCA IgG antibodies of Epstein-Barr virus (EBV) in a Spanish cohort of multiple sclerosis (MS) patients and their interactions with other environmental and genetic risk factors. 2. To analyze the association of the evolution of these antibodies with the clinical response to different disease modifying therapies (DMTs) after two-years of follow-up. 3. To assess their possible correlation with the class II HLA alleles as well as with several SNPs identified in GWAS related to disease susceptibility.

Materials and methods: We recruited 325 MS patients without DMT (serum samples were collected 1-3 months before starting a therapy) and 295 healthy controls (HC). For each patient we also collected serum samples 6, 12, 18 and 24 months after starting the DMT. EBNA-1 and VCA IgG titers were analyzed by ELISA; 25(OH)D levels were analyzed by immunoassay; HLA DRB1*15:01 allelic variant was analyzed by Taqman technology.

Results: 1. 97.8% (318/325) vs. 87.1% (257/295) positives for EBNA-1 in MS patients and HC, respectively (p<0.0001; O.R. = 6.7); 99.7% (324/325) vs. 94.6% (280/295) for VCA in MS patients and HC, respectively (p<0.0001; O.R. = 18.6). All MS patients were positive for EBNA-1 and/or VCA IgG antibodies vs. 280/295 (94.9%) HC (p<0.0001). IgG titers were also significantly higher in MS patients than in HC. 2. We did not find any statistical correlation in the variation of the EBNA-1 and VCA IgG titers between baseline and 24 month visits with the number of relapses, progression, clinical response, NEDA-3 condition or therapeutic failure. 3. When we compared different epidemiological and clinical variables between those with genetic factors associated with lower EBNA-1 IgG titers and all other MS patients, we found MS started 3.5 years later among the first.
Conclusions: These results confirm that MS occurs rarely in absence of EBV. An intriguing association between genetic burden and lower EBNA-1 IgG titers was associated with an earlier age of disease onset. Similar studies with B-cell–targeted therapies should be performed.

KEYWORDS
multiple sclerosis, Epstein-Barr virus, EBNA-1, VCA, HLA, GWAS, EOMES, vitamin D

Introduction

Multiple sclerosis (MS) is a neurological chronic inflammatory disease of the central nervous system (SNC) characterized by demyelination and axonal destruction in different degrees (1). Although the etiology of MS is still unknown, increasing evidences show that environmental factors could have a role in the disease. Among the related environmental factors, the infection by certain viruses have been associated with the development of MS (2), especially the Epstein-Barr virus (EBV) (3–5). Furthermore, it has been recently published that EBV could be the leading cause of MS (6); in this study, authors found that risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses.

Different disease modifying therapies (DMTs), such as interferon-beta (IFN-beta), glatiramer acetate (GA) or natalizumab (NTZ) are able to reduce the relapse rate and the rate of disability progression (7–9). Since DMTs are able to change the evolution of the disease, a relation between the clinical response to these DMTs and the viruses involved in MS could be demonstrated. Moreover, different genetic factors as human leukocyte antigen (HLA) allelic variants and other genetic variants identified by genome wide association studies (GWAS) are related to MS susceptibility (10). However, a significant proportion of MS heritability remains unexplained. Different explanations for the missing heritability in MS have been proposed, including gene-environment interactions.

Thus, the objectives of this study were: 1. To analyze the prevalence and levels of anti-EBNA-1 and anti-VCA IgG antibodies in a Spanish cohort of MS patients and their possible interactions with other environmental factors such as smoking habit and vitamin D and with the MS genetic risk factor HLA-DRB1*15:01. 2. To analyze the possible association of the evolution of the anti-EBNA-1 and anti-VCA IgG antibody titers with the clinical response to different disease modified therapies (DMTs) after two-years of follow-up. 3. To assess the possible correlation of the anti-EBNA-1 and anti-VCA IgG antibody titers with the class II HLA alleles as well as with several SNPs identified in GWAS related to disease susceptibility.

Materials and methods

Design

This is a retrospective study. Inclusion criteria: MS patients over 18 years old diagnosed by Poser (11) or 2010 McDonald (12) criteria with: (1) interferon-beta (IFN-beta), glatiramer acetate (GA) or natalizumab treatment for at least two years; (2) serum samples collected within a month before treatment onset and 24 months after treatment initiation; (3) expanded Disability Status Scale (EDSS) score at DMT onset and two years later; (4) number of relapses since the beginning of the disease and during the first two years of treatment; (5) an analysis of antibodies against IFN-beta in MS patients treated with this DMT. Exclusion criteria: pregnant woman and MS patients with secondary progressive or primary progressive diagnosis. A cohort of healthy controls was also included in the study to be compared with those MS patients before starting DMT; the inclusion criteria were: blood donors with more than 18 years old. Exclusion criteria for healthy controls: pregnant woman, first and second degree relatives with MS or with any other autoimmune disease.

Patients

Patients belonged to the following hospitals: Hospital Clinico San Carlos (Madrid) and Hospital Universitario Quirónsalud Madrid. Neurologists of the Multiple Sclerosis Units of those hospitals collected all the clinical data. Blood donors belonged to Hospital Clinico San Carlos.

Ethics statement

This study was approved by local Ethic Committees of the following centers: Comité Ético de Investigación Clínica del Hospital Clínico San Carlos and Comité de Ética de la Investigación del Hospital Fundación Jiménez Diaz (for patients recruited at Hospital Universitario Quirónsalud...
A written informed consent was received and signed for each one of the MS patients and controls recruited. All experiments were performed in accordance with relevant guidelines and regulations.

**Response criteria**

Progression was defined depending on pre-treatment Expanded Disability Status Scale (EDSS) score: 1) increase ≥1.5 points at 24-months visit if pre-treatment EDSS=0; 2) increase ≥1 point at 24-months visit if pre-treatment EDSS was ≥1 and ≤5; 3) increase ≥0.5 points at 24-months visit if pre-treatment EDSS was ≥5.5. We considered relapses as a worsening of neurological damage or a new symptom or other abnormality referable to MS; they should last at least 24 hours with a subsequently period of stability of at least one month. One month prior DMT onset was performed a magnetic resonance imaging (MRI) of the brain in 1.5T scanners following a previous published protocol (13); later MRIs were performed one and two years after starting these therapies. We collected the following sequences for this study: T1-weighted imaging with Gd enhancement, axial fluid-attenuated inversion recovery (FLAIR) T2, axial T2-weighted imaging and axial proton density T2-weighted imaging. To cover the entire brain we acquired slice thickness of 5 mm to analyze contiguous axial sections. With the previous definitions, the following response criteria were established after two years of follow-up: clinical response (defined as an absence of relapses and disability progression), therapeutic failure (≥2 relapses and/or disability progression), and NEDA-3 (no evidence of disease activity: no relapses, no disability progression, with no new T2 lesions or Gd+ lesions).

**Researched variables**

We analyzed the following variables in the MS group:

- Demographic, clinical and radiological: gender, age at disease onset, age at DMT onset, EDSS at DMT onset, progression of the disease after two-years of treatment, disease duration, number of relapses two-years after DMT onset and annualized relapse rate since the beginning of the disease, number of T2 and Gd+ lesions in the MRI performed at recruitment and 1 and 2 years after DMT onset.
- Genetic: Class II HLA alleles (including HLA DRB1*15:01 allelic variant), and SNPs related to MS susceptibility selected from GWAS (Supplementary Table 1).
- Environmental: IgG antibody response to EBV (EBNA-1 and VCA IgG titers), smoking habit (current smoker or not smoker) and 25(OH)D levels at baseline sample prior DMT onset.

The following variables were analyzed in the healthy control group:

- Demographic: gender and age at sample collection.
- Genetic: HLA DRB1*15:01 allelic variant.
- Environmental: IgG antibody response to EBV (EBNA-1 and VCA IgG titers), smoking habit (current smoker or not smoker) and 25(OH)D levels at sample collection.

**Serum samples**

For each patient and control we collected one dry tube with blood. After collection, blood was clotted by leaving it at room temperature for 30 minutes; later, clot was removed by centrifuging 10 minutes at 1,500xg in a refrigerated centrifuge. Lastly, serum samples were aliquoted, and aliquots were frozen at -80°C.

**EBNA-1 and VCA IgG ELISA**

Serum samples of MS patients and controls were tested with two tests of Trinity Biotech Captia™ (Bray, Co. Wicklow, Ireland), for the detection and quantification of anti-EBNA-1 and anti-VCA (BFRF3 antigen) IgG titers following manufacturer instructions, in an automated ELISA processing system (DS2, Dynex Technologies, USA). Results were expressed in arbitrary units (AU); they were calculated by multiplying the index value by 10 (the index value for each one of the samples = sample absorbance/cut-off value). Standard samples were run on each plate (the inter-assay coefficient of variation was under 5%). Samples from MS patients and healthy controls were analyzed in duplicate for each test. Those that were above 11 AU were considered positive and those that were below 9 AU were considered negative; doubtful samples, those that were between 9 and 11 AU were tested again.

**Detection of neutralizing antibodies (NAbs) against IFN-beta**

In those RRMS patients that were under IFN-beta treatment we measured NAbs through the cytopathic effect (CPE) assay (14). Titers were calculated according to Kawade’s formula (15), and they were expressed in tenfold reduction unit (TRU). Positive samples were those with titers > 20 TRU/ml.

**25(OH)D determination**

25(OH)D levels were analyzed by immunoassay (Abbot, Wiesbaden, Germany), following the manufacturer’s...
instructions. To normalize the data due to the seasonal variation, we calculate the median value of each semester (MVS) for MS patients and healthy controls: 16.9 ng/ml for the first semester of the year and 24.0 ng/ml for the second semester of the year, in MS patients; 19.8 ng/ml and 24.7 ng/ml, respectively, in healthy controls. Finally, we performed two groups for MS patients and healthy controls: those with 25(OH)D levels>MVS and those with 25(OH)D levels<MVS.

HLA genotyping

HLA Genotyping. Class II HLA-DR and -DQ was genotyped using SSOP technology (Sequence specific-oligonucleotide probe). HLA DRB1*15:01 allelic variant was analyzed by Taqman technology in a 7900HT Fast Real-Time PCR system, following manufacturer recommendations (Applied Biosystems, Foster City, CA, USA). Genotyping of different SNPs from GWAS was performed by iPLEX® Gold MassARRAY Sequenom technology at the National Center of Genotyping (CEGEN. Valencia, Spain). These SNPs were included in this study because they were available as they had been analyzed previously in different genetic studies performed in our MS patients. In Supplementary Table 1 are shown the SNPs included in this study.

Statistical analysis

The chi-square or two-tailed Fisher’s exact test was used to test differences in categorical variables. Kruskall-Wallis analysis or the Wilcoxon rank-sum test was used to test differences in continuous variables. For the genetic study, allele and genotype frequencies were compared by the Chi-square test. We considered statistically significant differences when \( p<0.05 \); \( p \)-values were corrected for multiple comparisons with the Bonferroni method. Odds ratios (O.R.) and exact 95 percent confidence intervals (C.I.) were obtained with the following software: Epi Info v. 6.02 (CDC, Atlanta, USA) and SPSS Ver. 15.0 (SPSS Inc.). The graphs were created with GraphPad Prism® 6.0.

Results

Patients eligible for the study and demographic characteristics of the population study

We recruited 325 relapsing-remitting MS (RRMS) patients that fulfilled all the inclusion criteria and 295 healthy controls (Table 1). Furthermore, from 246 MS patients and 295 healthy controls we had data from smoking habit; from 233 MS patients and 194 healthy controls we measured vitamin D levels at basal sample and at 24 month sample; from 315 MS patients and 270 healthy controls we assessed the HLA-DRB1*15:01 allelic variant; class II HLA-DR and -DQ were genotyped from 288 MS patients; 304 MS patients were genotyped for the SNPs shown at Supplementary Table 1; finally, from 215 MS patients we had MRI data.

Higher EBNA-1 and VCA IgG prevalence and titers in untreated MS patients than in healthy controls

We found statistical significant differences in the prevalence of EBNA-1 and VCA IgG antibodies between untreated MS patients (samples collected prior DMT onset) and healthy controls: 97.8% (318/325) vs. 87.1% (257/295) for EBNA-1 in MS patients and healthy controls, respectively (\( p=0.000003; \) O.R. = 6.7); 99.7% (324/325) vs. 94.6% (279/295) for VCA in MS patients and healthy controls, respectively (\( p=0.0001; \) O.R. = 18.6). Furthermore, all MS patients were positive for EBNA-1 and/or VCA IgG antibodies vs. 280/295 (94.9%) healthy controls (\( p=0.00004 \)). Regarding IgG titers, we also found statistical significant differences. The median value in MS patients was 25.4 AU for EBNA-1 and 59.9 AU for VCA vs. 24.2 AU for EBNA-1 and 55.5 AU for VCA in healthy controls (\( p=0.000001; \) for both IgG antibodies). Since major predisposing factors for MS, like HLA DRB1*15:01, vitamin D deficiency and smoking, have also been related with the IgG levels against EBV, we stratified according to them; comparisons between MS patients and healthy controls are shown in Table 2.

EBNA-1 and VCA IgG antibodies in MS patients prior DMT onset and healthy controls: correlation with clinical and demographical variables

We did not find any statistical difference in relation to the gender, nor in the untreated MS samples nor in the healthy control group (Supplementary Table 2). Regarding the age, we found a correlation with the VCA IgG titers in the untreated MS samples (\( r=0.180; p=0.001 \)) and in the control group (\( r=0.116; p=0.047 \); not significant after Bonferroni correction for multiple comparisons), but any correlation was not found with EBNA-1 (\( p=0.647 \) and \( p=0.393 \) for MS patients and controls, respectively).

We also analyzed possible correlations between EBNA-1 and VCA IgG titers with different clinical variables in the samples collected before DMT in the MS group (Table 3): we only found a negative correlation between EBNA-1 IgG titers and the number of relapses two-years before starting DMTs (\( r=−0.153; p=0.006 \)). Lastly, we stratified these variables according to smoking habit, vitamin D levels and HLA DRB1*15:01: VCA IgG titers were increased in smoker female MS patients in comparison with non-smoker female MS patients (\( p=0.001; \)
VCA IgG titers correlated with ARR in non-smoker MS patients ($r=-0.371; p=0.002$); finally, VCA IgG titers correlated with the age in non-smoker MS patients ($r=0.364; p=0.003$) and in non-carriers of HLA-DRB1*15:01 MS patients ($r=0.220; p=0.002$).

As we can see in Table 4, we did not find any statistical association between EBNA-1 and/or VCA IgG levels at the baseline visit (before DMT onset) and the progression of the disease, the number of relapses, the clinical response, or the therapeutic failure to any of the DMTs included in the study. The stratification according to smoking habit, vitamin D levels and HLA DRB1*15:01 did not yield any significant correlation (data not shown).

EBNA-1 and VCA IgG titers before DMT onset was not associated with the clinical response after two-years of follow-up

As we can see in Table 4, we did not find any statistical significant association between EBNA-1 and/or VCA IgG levels at the baseline visit (before DMT onset) and the progression of the disease, the number of relapses, the clinical response or the therapeutic failure after two years of follow-up with the different DMTs. Stratification according to smoking habit, vitamin D levels and HLA DRB1*15:01 did not yield any statistical significant difference for any clinical variable analyzed (data not shown).

EBNA-1 and VCA IgG titers variation after two years follow-up with DMTs did not correlate with the clinical response

We did not find any statistical correlation in the variation of the EBNA-1 and VCA IgG titers between the basal and the 24 month samples and the number of relapses, the progression of the disease, the clinical response, the NEDA-3 condition or the therapeutic failure to any of the DMTs included in the study. The stratification according to smoking habit, vitamin D levels and HLA DRB1*15:01 did not yield any significant correlation (data not shown).

EBNA-1 and VCA IgG titers before DMT onset were associated with different HLA alleles

In Figure 1 we can see the distribution of EBNA-1 and VCA IgG titers according to the HLA-DR of the MS patients included in the study. After Bonferroni corrections for multiple comparisons, we found the following statistical associations: 1) HLA-DR3+ MS patients and lower EBNA-1 IgG titers: 14/143 (9.8%) MS patients with the highest titers were HLA-DR3+ vs.

---

| TABLE 1 | Demographical characteristics of the patients and healthy controls included in the study at the recruitment. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **MS patients** | **Healthy controls** | | | | | | | | | |
| Males                      | 108 | 180 | | | | | | | | |
| Females                    | 217 | 115 | | | | | | | | |
| Previous treatments prior recruitment: | | | | | | | | | | |
| No previous treatments (naïve patients) | 184 | – | | | | | | | | |
| 1 treatment                | 92  | –  | | | | | | | | |
| 2 treatments               | 38  | –  | | | | | | | | |
| 2 or more treatments       | 11  | –  | | | | | | | | |
| Age at recruitment (years, med (P25-P75)) | 36.0 (30.0-42.0) | 39.0 (29.5-47.0) | | | | | | | | |
| Age at disease onset (years, med (P25-P75)) | 28.0 (24.0-34.0) | – | | | | | | | | |
| Disease duration at recruitment (months, med (P25-P75)) | 65.0 (18.0-118.0) | – | | | | | | | | |
| EDSS at recruitment (med (P25-P75)) | 2.0 (1.0-3.0) | – | | | | | | | | |
| Annualized relapse rate since MS diagnosis (med (P25-P75)) | 1.0 (0.6-1.7) | – | | | | | | | | |
| Number of relapses 2 years before recruitment (med (P25-P75)) | 2.0 (1.0-3.0) | – | | | | | | | | |
| DMTs initiated at recruitment: | | | | | | | | | | |
| Glatiramer acetate          | 83  (53 naïve) | – | | | | | | | | |
| Interferon beta            | 131 (123 naïve) | – | | | | | | | | |
| Natalizumab                | 111 (8 naïve) | – | | | | | | | | |
| HLA DRB1*15:01 carriers (per (n/N)) | 38.1 (120/315) | 16.3 (44/270) | | | | | | | | |
| Smoking habit: smokers at recruitment (per (n/N)) | 45.5 (112/246) | 24.7 (73/295) | | | | | | | | |

(med: median; P25, 25th percentile; P75, 75th percentile; EDSS, Expanded Disability Status Scale; per, percentage).
**TABLE 2** Comparisons of EBNA-1 and VCA IgG titers and prevalence between untreated MS patients and healthy controls after stratification according to HLA DRB1*15:01 allele, smoking habit and levels of vitamin D.

### A. EBNA-1 IgG

|                | HLA DRB1*15:01                  | NO HLA DRB1*15:01                  | p (Chi) | OR (95% CI) | p (t-St.) |
|----------------|--------------------------------|-----------------------------------|---------|-------------|-----------|
| **MS**         | n/N (%)                          | n/N (%)                           | Titors* | Titors*     | p (Chi)   | OR (95% CI) | p (t-St.) |
| 119/120 (99.2) | 25.5                             | 189/195 (96.9)                    | 25.2    | n.s.        | 3.8 (0.4-84.3) | n.s.       |
| **HC**         | n/N (%)                          | n/N (%)                           | Titors* | Titors*     | p (Chi)   | OR (95% CI) | p (t-St.) |
| 40/44 (90.9)   | 25.5                             | 198/226 (87.6)                    | 23.2    | n.s.        | 1.4 (0.4-5.1) | n.s.       |
| **p***         | 0.086                            | 0.004                             | 0.0004  | <0.00001    |           |           |
| **OR (95% CI)**| 11.9 (1.2-288.1)                 | 4.5 (1.7-12.3)                    |         |             |           |

|                | CURRENT SMOKER                   | NO SMOKER                         | p (Chi) | OR (95% CI) | p (t-St.) |
|----------------|----------------------------------|-----------------------------------|---------|-------------|-----------|
| **MS**         | n/N (%)                          | n/N (%)                           | Titors* | Titors*     | p (Chi)   | OR (95% CI) | p (t-St.) |
| 110/112 (98.2) | 25.3                             | 134/134 (100)                     | 25.5    | n.s.        |           |           |
| **HC**         | n/N (%)                          | n/N (%)                           | Titors* | Titors*     | p (Chi)   | OR (95% CI) | p (t-St.) |
| 68/73 (93.2)   | 22.3                             | 184/216 (85.2)                    | 24.2    | n.s.        | 2.4 (0.8-7.2) | n.s.       |
| **p***         | n.s.                             | <0.00001                          |         | <0.00001    |           |           |
| **OR (95% CI)**| 4.0 (0.7-31.1)                   | 25 (OH)D< MVS****                 |         |             |           |

**EBNA-1 and VCA IgG titers before DMT onset and SNPs from GWAS**

After Bonferroni correction for multiple comparisons, we found a statistical association between rs11129295 (located on chromosome 3 - EOMES gene) and EBNA-1 IgG titers: 25.7 AU, 25.3 AU and 24.2 AU were the median values of the EBNA-1 IgG titers for TT, CT and CC genotypes (p=0.0008. Kruskal
Wallis test) (p values for all the genotype and allele comparisons are in Supplementary Table 5, 6).

### Discussion

We found statistical significant differences in EBNA-1 and VCA IgG prevalences and titers between MS patients and controls. Furthermore, all MS patients were positive for EBV antibodies (EBNA-1 and/or VCA) but not the controls (94.9%,

Epidemiological and clinical data of MS patients according to the genetic background associated with EBNA-1 IgG titers

According to the genetic associations found, we compared different epidemiological and clinical data between DR3+/DR6-/rs11129295TT- MS patients and the rest of the patients. As we can see in Table 6, we found a statistical significant difference for the starting age of the disease: MS started 3.5 years later among those MS patients with genetic factors associated with lower EBNA-1 IgG titers.

**TABLE 3** Correlations between EBNA-1 and VCA IgG titers with different clinical variables in the samples collected before DMT onset in the MS group.

|                            | Starting Age | Disease duration | EDSS | Relapses 2-years before DMT onset | ARR   |
|-----------------------------|--------------|------------------|------|----------------------------------|-------|
| **EBNA-1 IgG titers**       | r            | 0.131            | -0.116 | -0.107                          | -0.153 | -0.073 |
|                            | p            | 0.018            | 0.036 | n.s.                            | 0.006  | n.s.   |
| **VCA IgG titers**          | r            | 0.113            | 0.067 | 0.075                           | -0.106 | -0.102 |
|                            | p            | 0.041            | n.s.  | n.s.                            | n.s.   | n.s.   |

Correlations were assessed by using the Spearman’s rank correlation coefficient (r). Bold values indicate the statistically significant values after Bonferroni correction (p<0.007); significant p values prior Bonferroni correction are also shown. ARR, annualized relapse rate (number of relapses since the beginning of the disease/duration of the disease [years]). n.s., not significant.

**TABLE 4** EBNA-1 and VCA IgG titers at baseline visit (prior DMT onset) and progression, number of relapses, clinical response and therapeutic failure after two years of follow-up with DMT.

|                            | EBNA-1 IgG | VCA IgG |
|-----------------------------|------------|---------|
|                            | PROGRESSION | PROGRESSION |
|                            | pos./N (%) | Titors* | pos./N (%) | Titors* |
| **PROGRESSION**             |            |         |            |         |
| YES                         | 51/53 (96.2) | 25.7    | 53/53 (100) | 59.1    |
| NO                          | 265/270 (98.1) | 25.3    | 269/270 (99.6) | 59.9    |
| **OR (95% CI)**             | n.s.       | n.s.    | n.s.       | n.s.    |
|                            | RELAPSES   | RELAPSES |
|                            | pos./N (%) | Titors* | pos./N (%) | Titors* |
| **RELAPSES**                |            |         |            |         |
| YES                         | 128/131 (97.7) | 25.5    | 130/131 (99.2) | 60.1    |
| NO                          | 190/194 (97.9) | 25.3    | 194/194(100)  | 59.4    |
| **OR (95% CI)**             | n.s.       | n.s.    | n.s.       | n.s.    |
|                            | CLINICAL RESPONSE | CLINICAL RESPONSE |
|                            | pos./N (%) | Titors* | pos./N (%) | Titors* |
| **CLINICAL RESPONSE**       |            |         |            |         |
| YES                         | 165/168 (98.2) | 25.3    | 168/168 (100) | 59.7    |
| NO                          | 153/157 (97.5) | 25.5    | 156/157 (99.4) | 59.9    |
| **OR (95% CI)**             | n.s.       | n.s.    | n.s.       | n.s.    |
|                            | THERAPEUTIC FAILURE | THERAPEUTIC FAILURE |
|                            | pos./N (%) | Titors* | pos./N (%) | Titors* |
| **THERAPEUTIC FAILURE**     |            |         |            |         |
| YES                         | 92/94 (97.9) | 25.6    | 94/94 (100) | 59.0    |
| NO                          | 226/231 (97.8) | 25.2    | 230/231 (99.6) | 60.1    |
| **OR (95% CI)**             | n.s.       | n.s.    | n.s.       | n.s.    |

*Median values of the arbitrary units (AU). **Student t test (for titers) and Chi-square test (for categorical variables). n.s., not significant.
Thus, these results confirm that MS occurs rarely in the absence of EBV as it has been previously suggested (6). After stratification by other predisposing factors for MS like HLA DRB1*15:01, vitamin D deficiency and smoking habit, EBNA-1 and VCA IgG prevalences and titers remained significantly higher in MS patients than in controls. A recent study with the Swedish cohort showed that smokers had higher EBNA-1 antibody levels than never smokers; authors suggested that smoking habit and EBNA-1 antibody levels could act synergistically to increase MS risk (16). Interestingly, we did not find a significant difference in EBNA-1 and VCA IgG prevalences between current smokers (MS patients and controls); a higher prevalence of both antibodies was found in the control group of current smokers than in the control group of no smokers, although this increase was not higher enough to be significantly different between both groups. Regarding vitamin D, MS and EBV, it has been published that high-dose vitamin D supplementation reduces anti-EBNA-1 antibody levels in MS patients (17); also, EBV viral load measured by quantitative PCR was significantly higher when vitamin D levels were low, demonstrating an inverse correlation between vitamin D and EBV viral load (18). Furthermore, a previous study showed monthly differences in EBNA-1 IgG levels and an association between EBNA-1 IgG, vitamin D levels and HLA-DRB1*15 indicating that EBNA-1 IgG serum levels could be affected by genetic and environmental factors (19). In our study, we did not find significant differences in EBNA-1 or VCA IgG prevalences or titers in relation to HLA-DRB1*15:01 or the vitamin D levels nor in MS group nor in control group.

**TABLE 5** Prevalences and median titers of the anti-EBNA-1 and VCA IgG antibodies before and after 2-years of treatment with the different DMTs.

| DMTs  | Anti-EBNA-1 IgG | Anti-VCA IgG |
|-------|----------------|-------------|
|       | Prevalences     | Median Titers (AU)* | Prevalences     | Median Titers (AU)* |
|       | Before          | 2-years      | p            | Before          | 2-years      | p            |
| TOTAL | 97.8% (318/325) | 98.5% (320/325) | n.s.         | 25.4           | 25.7         | n.s.         |
| IFN-beta | 96.9% (127/131) | 97.7% (128/131) | n.s.         | 25.9           | 26.2         | n.s.         |
| GA    | 98.8% (82/83)   | 98.8% (82/83)   | n.s.         | 25.4           | 26.0         | n.s.         |
| NTZ   | 98.2% (109/111) | 99.1% (110/111) | n.s.         | 24.9           | 24.9         | n.s.         |

TOTAL prevalence and median titers of all the different disease modifying therapies (DMTs); IFN-beta, interferon beta; GA, glatiramer acetate; NTZ, natalizumab. *Median values of the arbitrary units (AU). **Student t test (for titers) and Chi-square test (for categorical variables). n.s., not significant.

**Figure 1**

EBNA-1 (A) and VCA (B) IgG titres in serum samples of MS patients prior DMT treatment according to HLA-DR. Grey points correspond to EBNA-1 and VCA IgG values in AU of each sample; in black, mean plus standard error of the mean for each HLA-DR.
When we analyzed possible correlations between EBV IgG antibodies and clinical and demographic variables prior DMT onset, we found a positive significant correlation between VCA IgG titers and the age of MS patients (but with a very low correlation coefficient). A previous study with Lebanese MS patients also found that older age was associated with a higher anti-VCA titer (20). Similarly, we found an inverse low correlation (although significant) between EBNA-1 IgG titers and the annualized relapse rate two years prior recruitment. Prior results also suggested that anti-EBNA-1 IgG levels in MS could not be a reliable marker of MS clinical disease activity (21, 22). However, both data should be analyzed in further studies with wider cohorts to better understand their possible clinical relevance.

In this study we also analyzed the possible association between the EBNA-1 and VCA IgG variation after two years of follow-up with the clinical response to different DMTs in the same period. However, we did not find any relation between EBV IgG antibodies variation and the clinical parameters analyzed between the basal visit (without treatment) and the 24 month visit (after two years with different DMT). Previous articles found similar results. Raffel et al. (23) investigated the effect of interferon-beta and natalizumab therapy on prospective sera anti-EBNA-1 IgG titres over 12 months of treatment; for both, there was no significant difference between pre-therapy and post-therapy anti-EBNA-1 IgG titres. In a study of Comabella et al. (24), they evaluated cellular and humoral immune responses to EBV encoded antigens in patients with MS before and 1 year after interferon-beta treatment by ELISA and flow cytometry; although clinically effective interferon-beta therapy was associated with a downregulation of proliferative T cell responses to the latent EBNA-1, EBNA1-specific IgG responses as well as cellular and humoral immune responses to MHC class I restricted EBV antigens expressed during lytic replication and viral B cell transformation were similar before and after interferon-beta therapy. Therefore, it seems that these treatments would not have an effect on EBV antibody titers. This is probably related to their mechanisms of action and with the cell populations that could be modified by them. But, what about those new MS therapies that have B-cells as primary target? The emerging B-cell depleting therapies, particularly anti-CD20 monoclonal antibodies, would deplete the primary site of EBV latent infection. Thus, it has been suggested that the high efficacy described for these treatments (25, 26) could be associated, at least in part, with their effects on EBV. There are not previous studies with these therapies on EBV viral load or antibody titers in MS patients. However, a study with a small cohort of MS patients that initiated ocrelizumab showed that this treatment decreases the cellular immune response to EBV as measured by in vitro proliferation and IFN-gamma secretion (27). In another publication, a 56-year-old woman with EBV-associated posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation was treated with ofatumumab, with a significant decrease in EBV viral load (28). Therefore, it would be of great interest to perform longitudinal studies with these therapies to analyze the possible correlation between the clinical response and the variation in the EBV viral loads or antibody titers.

Finally, we also analyzed the possible association between the EBNA-1 and VCA IgG titers with the genetic background of the MS patients in serum samples collected when they were untreated. As we can see in the results section, we found several significant associations: HLA-DR3+ with lower EBNA-1 IgG titers, HLA-DR6+ with higher EBNA-1 IgG titers and rs11129295TT carriers with higher EBNA-1 IgG titers. Prior studies have found different significant correlations between HLA alleles and EBV viral load and antibody titers in different MS cohorts; thus, it has been suggested that the mechanism through which HLA genes would influence the risk of MS may, at least in part, involve the immune control of EBV infection (29, 30). This is the first study performed in Spanish MS patients that evaluate the possible interaction between different genetic factors.
and the levels of EBNA-1 and VCA IgG titers. Beside the HLA alleles cited above, we also found a statistical significant association for the rs11129295TT genotype and rs11129295T allele. This SNP is located on chromosome 3 and is associated with the expression of the transcription factor EOMES which is induced in effector CD8+ T cells in vitro and in vivo (31). Furthermore, CD8+ T cells deficient in this transcription factor fail to differentiate into functional killers (32); also, mature NK cells from which EOMES was deleted reverted to phenotypic immaturity (33). In MS patients it has been described that EOMES expression is significantly lower than in healthy controls (34); that could mean a worse control of infections, like EBV, in MS. An analysis of twins from the Brisbane Systems Genetics Study determined that the heritability of EOMES was 0.48, although it could be underestimat; besides, EOMES expression was normalized to healthy control levels with MS therapies like natalizumab (35). In our study, when we compared different epidemiological and clinical variables between those with genetic factors associated with lower EBNA-1 IgG titers and all other MS patients, we found MS started 3.5 years later among the first. Previously, the HLA burden, especially the DRB1*1501 allele, had been associated on average to a younger age at onset (36, 37). In our Spanish cohort of MS patients, we found that the combination of different HLA alleles and a no-HLA SNP could be associated with a different MS phenotype that should be further studied.

Among the limitations of the study, it has to be considered the absence of HLA class I data; given the result on EOMES, a transcription factor that may affect the CD8 response, genotyping for HLA class I would have been of interest. In addition, it would be very interesting to study the expression levels of EOMES and try to correlate them with the EBNA-1 titers in a longitudinal study like this and also to analyze the expression levels of this transcription factor according to EOMES genotyping.

In conclusion, these results confirm that MS occurs rarely in absence of EBV. Although other predisposing factors could be involved in MS pathology, prevalences and titers remained significantly higher in MS patients than in controls after stratification by them. Besides, an intriguing association between genetic burden and lower EBNA-1 IgG titers was associated with an earlier age of disease onset. Finally, the DMTs included in this study did not change significantly the titers of the anti-EBV antibodies analyzed; similar studies with B-cell–targeted therapies are needed.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

The studies involving human participants were reviewed and approved by Comité Ético de Investigación Clinica del Hospital Clínico San Carlos and Comité de Ética de la Investigación del Hospital Fundación Jiménez Díaz. The patients/participants provided their written informed consent to participate in this study.

Author contributions

MD-M, LL-L and RA-L made substantial contributions to the conception or design of the work, the acquisition, analysis, and interpretation of data for the work, and drafting the work or revising it critically for important intellectual content. SP-P performed analysis, and interpretation of data for the work, and drafting the work or revising it critically for important intellectual content. AG-M took part in the acquisition of the data. MT took part in the acquisition of the data and drafting the work or revising it critically for important intellectual content. RA contributed drafting the work or revising it critically for important intellectual content. All authors contributed to the article and approved the submitted version.

Funding

This work was financially supported by Instituto de Salud Carlos III (ISCIII)-Fondo Europeo de Desarrollo Regional (Feder) (P118/00204), "REEM: Red Española de Esclerosis Múltiple" (RD16/0015/0013) and "Fundación LAIR".

Conflict of interest

RA has been a speaker or has participated in the advisory board of Novartis, Teva, Roche, Bristol, Janssen, Biogen, Merck and Sanofi-Genzyme. RA-L has received support for attending meetings from Biogen, Novartis and Sanofi-Genzyme.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.991662/full#supplementary-material
References

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med (2000) 343:938–52. doi: 10.1056/NEJM200009283431407

2. Tsuji A. Evidence for viral etiology of multiple sclerosis. Semin Neurol (2011) 31:307–16. doi: 10.1055/s-0031-1287566

3. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, et al. Epstein-Barr Virus antibodies and risk of multiple sclerosis: a prospective study. JAMA (2000) 286:3083–8. doi: 10.1001/jama.286.24.2436

4. Levin LK, Munger KL, Robertette MV, Peck CA, Lennette ET, Spiegelman D, et al. Temporal relationship between elevation of Epstein-barr virus antibody titters and initial onset of neurological symptoms in multiple sclerosis. JAMA (2005) 293:2496–500. doi: 10.1001/jama.293.20.2496

5. Salvetti M, Giovannoni G and Aloisi F. Epstein-Barr Virus and multiple sclerosis. Curr Opin Neurol (2009) 22:201–6. doi: 10.1097/WCO.0b013e3282b8c4d8

6. Bjørnevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr Virus associated with multiple sclerosis. Science (2022) 375:296–301. doi: 10.1126/science.abv2222

7. Comi G, Martinelli V, Rodigher M, Moola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCIsE study): a randomised, double-blind, placebo-controlled trial. Lancet (2009) 374:1503–10. doi: 10.1016/S0140-6736(09)61259-9

8. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing-remitting multiple sclerosis. The low EOMES/TBX21 molecular phenotype in multiple sclerosis re...Mult Scler (2014) 20:30049. doi: 10.1177/1352458513498982

9. Reif L, Maris AH, Mathias A, Du Pasquier R, Konecny I, Disanto G, et al. Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Mult Scler (2018) 24:1280–7. doi: 10.1177/1352458517722846

10. Pérez-Pérez S, Domínguez-Mozo MJ, García-Martínez MA, Aladro Y, Martínez-Gines M, García-Dominguez JM. On the study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis. Eur J Neurol (2018) 25:1446–53. doi: 10.1111/ene.143749

11. Peñalva MA, Olek MJ, Munger KL, Sas MS, Pedrosa C, Kiese R, et al. Multiple sclerosis therapy and Epstein-Barr virus antibody titers. Multiple Sclerosis and related disorders (2017) 100378. doi: 10.1016/j.msard.2017.10.003

12. Raffel J, Mohsen S, Afzal A, Strother J, Murocchi M, Polman CH, et al. mRNA expression of IFN-related genes in multiple sclerosis patients treated with rituximab therapy. J Neuroinflammation (2018) 15:205. doi: 10.1186/s12974-018-1209-4

13. Roff L, Weis EA, Manzulla S, Márquez JM, et al. Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis. Eur J Neurol (2018) 25:1446–53. doi: 10.1111/ene.143749

14. Rolda A, Terzi I, Giardina S, Lanzavecchia A, Yelamos J, et al. Multiple sclerosis and surrounding diseases. Curr Opin Neurol (2015) 28:169–76. doi: 10.1097/WCO.0000000000000247

15. Rolda A, Terzi I, Giardina S, Lanzavecchia A, Yelamos J, et al. Multiple sclerosis and surrounding diseases. Curr Opin Neurol (2015) 28:169–76. doi: 10.1097/WCO.0000000000000247

16. Hedström AK, Huang J, Brenner J, Lennette ET, Spiegelman D, et al. Temporal relationship between elevation of Epstein-barr virus antibody titters and initial onset of neurological symptoms in multiple sclerosis. JAMA (2005) 293:2496–500. doi: 10.1001/jama.293.20.2496

17. Comi G, Martinelli V, Rodigher M, Moola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCIsE study): a randomised, double-blind, placebo-controlled trial. Lancet (2009) 374:1503–10. doi: 10.1016/S0140-6736(09)61259-9

18. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing-remitting multiple sclerosis. The low EOMES/TBX21 molecular phenotype in multiple sclerosis re...Mult Scler (2014) 20:30049. doi: 10.1177/1352458513498982

19. Peñalva MA, Olek MJ, Munger KL, Sas MS, Pedrosa C, Kiese R, et al. Multiple sclerosis therapy and Epstein-Barr virus antibody titers. Multiple Sclerosis and related disorders (2017) 100378. doi: 10.1016/j.msard.2017.10.003

20. Raffel J, Mohsen S, Afzal A, Strother J, Murocchi M, Polman CH, et al. mRNA expression of IFN-related genes in multiple sclerosis patients treated with rituximab therapy. J Neuroinflammation (2018) 15:205. doi: 10.1186/s12974-018-1209-4

21. Raffel J, Mohsen S, Afzal A, Strother J, Murocchi M, Polman CH, et al. mRNA expression of IFN-related genes in multiple sclerosis patients treated with rituximab therapy. J Neuroinflammation (2018) 15:205. doi: 10.1186/s12974-018-1209-4

22. Roff L, Weis EA, Manzulla S, Márquez JM, et al. Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis. Eur J Neurol (2018) 25:1446–53. doi: 10.1111/ene.143749

23. Rolda A, Terzi I, Giardina S, Lanzavecchia A, Yelamos J, et al. Multiple sclerosis and surrounding diseases. Curr Opin Neurol (2015) 28:169–76. doi: 10.1097/WCO.0000000000000247

24. Roff L, Weis EA, Manzulla S, Márquez JM, et al. Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis. Eur J Neurol (2018) 25:1446–53. doi: 10.1111/ene.143749

25. Rolda A, Terzi I, Giardina S, Lanzavecchia A, Yelamos J, et al. Multiple sclerosis and surrounding diseases. Curr Opin Neurol (2015) 28:169–76. doi: 10.1097/WCO.0000000000000247